Epimede
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Epimede - overview
Established
2007
Location
Liege, -, Belgium
Primary Industry
Business Support Services
About
Épimède Capital invests in high-growth technological small and medium-sized enterprises, focusing on life sciences, engineering, and corporate services, while actively engaging in their strategic decisions to foster innovation and growth within Wallonia. Épimède Capital is a private fund based in Liège, Belgium, specializing in investments in high-growth SMEs in technology sectors. The firm was founded by seasoned entrepreneurs committed to supporting promising firms in life sciences and engineering. The company has operated without notable pivots or changes in business strategy since its inception, focusing on its core investment philosophy.
Liège serves as the headquarters, and the firm is dedicated to enhancing businesses in the Wallonia region. Épimède Capital is a private fund targeting high-growth technological SMEs for investment, particularly in life sciences, engineering sciences, and corporate services. The firm actively participates in the boards of its portfolio companies, aligning its investments with their growth trajectories. Emphasizing support for businesses in Wallonia, Épimède provides financial assistance tailored to the unique needs of early-stage companies with technological advantages, fostering innovation and development within the region.
In 2022, Épimède Capital reported an EBITDA of EUR -654,723. 80, generated primarily through equity investments in high-growth SMEs. The firm acquires stakes in these companies, establishing a financial interest in their success. Revenue is augmented through strategic partnerships that develop as these companies scale and enhance their market offerings, creating a collaborative environment conducive to mutual financial benefit.
Épimède Capital is focused on expanding its investment portfolio into new markets, particularly targeting sectors that align with emerging technologies and innovations. The firm plans to leverage its recent funding to enhance its strategic engagements with portfolio companies, ensuring that their growth plans are supported with tailored financial solutions. Specific details on upcoming products or markets are currently undisclosed.
Primary Industry
Business Support Services
Sub Industries
Consulting Services
Website
http://epimede.com/en/
Total Amount Raised
Subscriber access only
Epimede - financials
| Fiscal Year Ended | Jun 30, 2016 | Jun 30, 2017 | Jun 30, 2018 | Jun 30, 2019 | Jun 30, 2020 | Jun 30, 2021 | Jun 30, 2022 | Jun 30, 2023 | Jun 30, 2024 | Jun 30, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (435,571) | (529,011) | (657,487) | (883,297) | (835,880) | (1,306,527) | (580,632) | - | - | - |
| Operating Income (USD) | (435,913) | (530,310) | (658,786) | (884,596) | (837,223) | (1,307,440) | (580,632) | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - | - | - |
| NET Income (USD) | (528,258) | (1,312,027) | (2,976,522) | (4,015,655) | (3,193,825) | 5,878,025 | 4,747,628 | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.